Free Trial
→ BREAKING: Doctors 'Cut & Paste' Diabetes from 42-year old (From Behind the Markets) (Ad)tc pixel Buy AZN with Qtrade  Free AZN Stock Alerts

AstraZeneca (AZN) Stock Forecast & Price Target

AstraZeneca logo
$79.85 -1.25 (-1.54%)
As of 11:13 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare

AstraZeneca - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Moderate Buy
Based on 4 Analyst Ratings
Sell
0
Hold
1
Buy
3

Based on 4 Wall Street analysts who have issued ratings for AstraZeneca in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 4 analysts, 1 has given a hold rating, and 3 have given a buy rating for AZN.

Consensus Price Target

$86.00
7.70% Upside
According to the 4 analysts' twelve-month price targets for AstraZeneca, the average price target is $86.00. The highest price target for AZN is $97.00, while the lowest price target for AZN is $75.00. The average price target represents a forecasted upside of 7.70% from the current price of $79.85.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for AZN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for AstraZeneca and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AZN Analyst Ratings Over Time

TypeCurrent Forecast
9/12/24 to 9/12/25		1 Month Ago
8/13/24 to 8/13/25		3 Months Ago
6/14/24 to 6/14/25		1 Year Ago
9/13/23 to 9/12/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
2 Strong Buy rating(s)
2 Strong Buy rating(s)
Buy
3 Buy rating(s)
4 Buy rating(s)
5 Buy rating(s)
7 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$86.00$86.00$85.00$89.75
Forecasted Upside7.70% Upside10.34% Upside14.22% Upside13.67% Upside
Consensus RatingModerate BuyModerate BuyBuyBuy

AZN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AZN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

AstraZeneca Stock vs. The Competition

TypeAstraZenecaMedical CompaniesS&P 500
Consensus Rating Score
2.75
2.78
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside6.04% Upside17,106.86% Upside9.67% Upside
News Sentiment Rating
Positive News

See Recent AZN News
Positive News
Positive News
Export to Excel
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
7/9/2025Berenberg Bank
2 of 5 stars
Luisa Hector
Not Rated
Set Target$97.00+37.02%
4/15/2025BNP Paribas
4 of 5 stars
P. Verdult
Not Rated
Initiated CoverageOutperform$75.00+11.09%
2/13/2025UBS Group
4 of 5 stars
M. Weston
Not Rated
UpgradeNeutral ➝ Buy
2/12/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Initiated CoverageOverweight
11/6/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 UpgradeSell ➝ Hold
9/11/2024Erste Group Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 UpgradeHold ➝ Buy
8/12/2024TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Boost TargetBuy$90.00 ➝ $95.00+16.29%
6/24/2024Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
P. Verdult
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
UpgradeStrong-Buy
6/24/2024Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
E. Field
Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating
UpgradeStrong-Buy
5/30/2024Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Boost TargetBuy$80.00 ➝ $85.00+10.72%
5/30/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Initiated CoverageBuy$97.00+27.50%
4/26/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Boost TargetOutperform$80.00 ➝ $82.00+8.70%
1/3/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 DowngradeBuy ➝ Hold
12/18/2023HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		 Initiated CoverageBuy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 11:05 AM ET.


Should I Buy AstraZeneca Stock? AZN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, September 11, 2025. Please send any questions or comments about these AstraZeneca pros and cons to contact@marketbeat.com.

AstraZeneca
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in AstraZeneca:

  • The current stock price is around $81, reflecting a strong market position and investor confidence.
  • AstraZeneca reported a quarterly revenue increase of 16.1% compared to the same quarter last year, indicating robust growth and demand for its products.
  • The company has a solid net margin of 14.68%, showcasing its ability to convert revenue into profit effectively.
  • A return on equity of 32.84% suggests that AstraZeneca is efficient in generating profits from its shareholders' investments.
  • Analysts have a consensus target price of $86, indicating potential upside for investors based on current valuations.

AstraZeneca
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in AstraZeneca for these reasons:

  • The company recently cut its dividend, which may signal financial caution and could deter income-focused investors.
  • Despite strong revenue growth, the earnings per share (EPS) decreased from $1.24 to $1.09 year-over-year, indicating potential challenges in maintaining profitability.
  • The stock has a relatively high P/E ratio of 30.53, which may suggest that it is overvalued compared to its earnings.
  • Market volatility could impact AstraZeneca's stock performance, as indicated by its beta of 0.37, which reflects lower volatility compared to the market.
  • Institutional ownership is at 20.35%, which may indicate a lack of confidence from larger investors in the company's future prospects.

AZN Forecast - Frequently Asked Questions

According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for AstraZeneca is $86.00, with a high forecast of $97.00 and a low forecast of $75.00.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There is currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AZN shares.

According to analysts, AstraZeneca's stock has a predicted upside of 7.70% based on their 12-month stock forecasts.

AstraZeneca has been rated by research analysts at Berenberg Bank in the past 90 days.

Analysts like AstraZeneca less than other "medical" companies. The consensus rating score for AstraZeneca is 2.75 while the average consensus rating score for "medical" companies is 2.78. Learn more on how AZN compares to other companies.

Related Companies
Today's Ratings
Top-Rated Stocks
More Ratings Tools

This page (NASDAQ:AZN) was last updated on 9/12/2025 by MarketBeat.com Staff
From Our Partners
Stunning new initiative unfolding in the White House?
what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...
Paradigm Press | Sponsoredtc pixel
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...
Porter & Company | Sponsoredtc pixel
Your Bank Account Is No Longer Safe
What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...
Priority Gold | Sponsoredtc pixel
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsoredtc pixel
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
Starting as soon as a few months from now, the United States government will make a sweeping change to bank ac...
Weiss Ratings | Sponsoredtc pixel
Alert: Prepare for Trump's Dollar Overhaul
President Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...
Brownstone Research | Sponsoredtc pixel
Forget NVDA. Put $1,000 into this stock now
A massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...
Chaikin Analytics | Sponsoredtc pixel
Trump’s Plan May Undo 1933’s Biggest Financial Injustice
Trump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...
American Hartford Gold | Sponsoredtc pixel